Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kimia Bagheri has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The impact of teleradiology: balancing clinical benefits and operational limitations

    by Reza Mosaddeghi-Heris, Kimia Bagheri, Ali Adib, Amir Tahavvori, Hadi Sahrai, Ali Norouzi, Saba Mehrtabar, Niloofar Taheri, Maryam Farzaneh, Houman Sotoudeh

  • Open Access

    Exploring the Role of Long Non-Coding RNAs in Mediating Cisplatin Resistance in Glioma/Glioblastoma Cells

    by Hadi Sahrai, Reza Mosaddeghi-Heris, Nasrin Forghani, Ali Norouzi, Sahand Zare, Hamed Aghazadeh, Kimia Bagheri, Rebecca Kocsis, Firoz Ahmed, Niloofar Taheri, et al.

    Malignant gliomas are highly aggressive primary brain tumors for which the therapeutic efficacy of cisplatin is frequently limited by intrinsic or acquired drug resistance. Despite advances in adjuvant therapies, overcoming chemoresistance remains a major challenge in the treatment of these malignancies. Emerging evidence indicates that long non-coding RNAs (lncRNAs), a class of non-protein-coding transcripts involved in gene regulation, play important roles in modulating treatment responses. Several lncRNAs, including differentiation antagonizing non-protein-coding RNA (DANCR), HOXD antisense growth-associated long non-coding RNA (HOXD-AS1), MEG3, MALAT1, and HOTAIR, have been implicated in pathways associated with glioma progression and therapeutic resistance. In particular, DANCR has been reported to promote cisplatin resistance in glioma cells through suppression of apoptosis and activation of pro-survival signaling pathways. This review summarizes current evidence regarding the roles of lncRNAs in cisplatin resistance, highlighting mechanisms such as regulation of drug transport, DNA damage repair, apoptosis, cancer stem-cell maintenance, and signaling pathways associated with treatment adaptation. We also discuss current limitations, challenges for clinical translation, and gaps in the existing evidence. A better understanding of lncRNA-mediated resistance mechanisms may facilitate the identification of novel therapeutic targets and inform future studies aimed at overcoming cisplatin resistance in malignant gliomas.

  • Open Access

    Stinging Salvation: Harnessing Scorpion Venom Peptides for Revolutionary Pain Relief

    by Reza Mosaddeghi-Heris, Mojtaba Pandeh, Leila Ghorbi, Niloofar Taheri, Maedeh Shariat Zadeh, Kimia Bagheri, Paolo Martelletti

    Peptides from scorpion venom, mainly in species such as Olivierus martensii (formerly Olivierus martensii Karsch, often designated BMK) (BmK) and Tityus serrulatus from the Buthidae family, show real promise as painkillers that skip opioids altogether. They work by hitting specific ion channels and dialing down inflammation. This review gathers information on their molecular setups: disulfide-bridged types and those without, weighing in at 3 to 10 kilodaltons (kDa). Structural features include motifs stabilized by cysteines. In pain signaling, they block voltage-gated sodium channels (NaV) such as NaV1.7 and NaV1.8; take the BmK analgesic–antitumor peptide (BmK-AGAP) for example. Additionally, scorpion venom heat-resistant peptide (SVHRP) reduces microglia activity. Tests on rodents using formalin injections, acetic acid writhing, and chronic constriction injury (CCI) setups reveal pain relief that depends on dose and stacks up to morphine. Pairings like AGAP with lidocaine decrease the effective dose by half. In terms of safety, therapeutic levels have low-toxicity with a median lethal dose (LD50) over 20 mg/kg. Issues crop up with immune responses, unintended targets, and differences in venom batches. Clinical information remains thin, so gaps persist. Engineered versions could change the game for neuropathic pain, inflammatory conditions, and cancer-related discomfort. Standardization plus Phase I studies would help move this forward.


  • The Hepatoprotective Effects of Ginsenoside from Ginseng: A Review of Molecular Mechanisms and Therapeutic Potentials

    by Seyed Reza Taha, Andarz Fazlollahpour-Naghibi, Mahdieh Shariat Zadeh, Kimia Bagheri, Hamed Rahmani Youshanlouei, Reza Mosaddeghi-Heris, Seyyed Sina Hejazian, Amirreza Khalaji, Seyedeh Shaghayegh Alavi, Payam Fattahi, et al.

    Treatment of hepatic diseases presents a significant challenge due to their diverse nature. Ginsenosides, bioactive compounds derived from the root of Panax ginseng and widely used in traditional Chinese medicine, offer multifaceted protection to various organs in the body. Their versatile effects, including antioxidant, anti-inflammatory, anti-apoptotic and more, make them a promising approach for addressing hepatic disorders. This review explores the intricate molecular mechanisms and properties of ginsenosides in the prevention and treatment of liver ailments, from mild conditions to severe damage and liver fibrosis. Given the increasing prevalence of hepatic disorders, this article sheds light on the significant pharmaceutical potential of ginsenosides in the realm of hepatic disease management.


  • Open Access

    The global prevalence of Trichuris trichiura infection in humans (2010-2023): A systematic review and meta-analysis

    by Hamed Behniafar, Mahdi Sepidarkish, Mehrdad Jafari Tadi, Soghra Valizadeh, Mostafa Gholamrezaei, Faezeh Hamidi, Hossein Pazoki, Faezeh Alizadeh, Nazanin Kianifard, Morteza Sheikhi Nooshabadi, et al.


  • Open Access

    Macrophage-Based Therapeutic Strategies in Hematologic Malignancies

    by Saeed Khalili, Fatemeh Zeinali, Atousa Moghadam Fard, Seyed Reza Taha, Andarz Fazlollahpour Naghibi, Kimia Bagheri, Mahdieh Shariat Zadeh, Yeghaneh Eslami, Khashayar Fattah, Naghmeh Asadimanesh, et al.

    Macrophages are types of immune cells, with ambivalent functions in tumor growth, which depend on the specific environment in which they reside. Tumor-associated macrophages (TAMs) are a diverse population of immunosuppressive myeloid cells that play significant roles in several malignancies. TAM infiltration in malignancies has been linked to a poor prognosis and limited response to treatments, including those using checkpoint inhibitors. Understanding the precise mechanisms through which macrophages contribute to tumor growth is an active area of research as targeting these cells may offer potential therapeutic approaches for cancer treatment. Numerous investigations have focused on anti-TAM-based methods that try to eliminate, rewire, or target the functional mediators released by these cells. Considering the importance of these strategies in the reversion of tumor resistance to conventional therapies and immune modulatory vaccination could be an appealing approach for the immunosuppressive targeting of myeloid cells in the tumor microenvironment (TME). The combination of reprogramming and TAM depletion is a special feature of this approach compared to other clinical strategies. Thus, the present review aims to comprehensively overview the pleiotropic activities of TAMs and their involvement in various stages of cancer development as a potent drug target, with a focus on hematologic tumors.